In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares and discusses the potential impact of AI-driven drug discovery platforms.
In this interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses the potential impact of AI-driven drug discovery platforms like DeepSeek and Qwen, highlighting their democratizing potential while also acknowledging challenges related to data quality and validation. The conversation explores the potential disruptions to current R&D practices, including the acceleration of drug discovery and the optimization of manufacturing and supply chains.
The discussion also addresses the potential risks associated with relying heavily on open-access AI models, including data security, intellectual property concerns, and the potential for biases in underlying datasets. Finally, the interview touches upon the environmental impact of AI, emphasizing the energy consumption of large language models while acknowledging the potential for AI to improve efficiency and reduce the environmental footprint of drug development.
First and foremost, the huge difference is that DeepSeek is coming out with a clear and true open access platform for all different types of researchers to be able to leverage those models. This is probably the key difference which makes the AI technology more accessible for maybe smaller research centers or smaller pharmaceutical providers that may not necessarily have the budgets of the large pharmaceutical companies. The challenge in that is, depending on how the information flows through these platforms, there may be some quality concerns in terms of the data that is being inputted in the models and how companies like DeepSeek may be doing proper data cleansing.
There is on one side, the democratizing of the of the AI, as a lot of providers are trying to push for. On the other, the less strict the barrier for entry is, the less chances there are to maintain the high level of quality that is absolutely paramount in something like drug discovery — where a small tweak into a molecule may cause extremely high and serious side effects into the actual outcome of the potential drug.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.